```html

Uveitis Granulomatosa (Sarcoidosis of the Eye)

Overview

Uveitis granulomatosa, more commonly referred to as ocular sarcoidosis, is an inflammatory eye disease that occurs when granulomas (tiny clusters of inflammatory cells) form within the uveal tract—the middle layer of the eye that includes the iris, ciliary body, and choroid. It is a manifestation of systemic sarcoidosis, a multisystem granulomatous disorder of unknown etiology.

Who it affects: Anyone can develop ocular sarcoidosis, but it is most frequently diagnosed in adults between 20‑50 years of age. Women are slightly more likely than men to be affected, and the condition is more prevalent in African‑American and Scandinavian populations.<sup>Mayo Clinic</sup>

Prevalence: Sarcoidosis affects about 10–30 per 100,000 people worldwide, with ocular involvement reported in 20‑40 % of systemic cases.<sup>CDC</sup> In the United States, ocular sarcoidosis accounts for roughly 5‑10 % of all cases of uveitis.<sup>NIH</sup>

Symptoms

Symptoms may be subtle at first, but prompt recognition is essential to prevent vision loss. Common features include:

• Redness of the eye – Often painless, may be mistaken for conjunctivitis.
• Blurred or decreased vision – Especially when inflammation involves the posterior segment.
• Floaters – Small, shadowy shapes that drift across the visual field, indicating vitreous inflammation.
• Photophobia – Sensitivity to light, more prominent with anterior uveitis.
• Eye pain – Typically dull and worsens with eye movement.
• Irregular pupil shape – Posterior synechiae (adhesions) can cause a “misshapen” pupil.
• Dry eye sensation – Result of reduced tear production from inflammation.
• Night vision loss – Happens when the retina or choroid is affected.
• Decreased contrast sensitivity – Difficulty distinguishing subtle shades.
• Headache – Occasionally associated with chronic inflammation.

Causes and Risk Factors

The exact cause of sarcoidosis is unknown, but current research points to an exaggerated immune response to an unidentified antigen (possibly environmental or infectious). The formation of non‑caseating granulomas in the eye mirrors the process occurring elsewhere in the body.

Key risk factors

• Genetics – Certain HLA‑DRB1 and HLA‑DQ alleles increase susceptibility.
• Race/Ethnicity – Higher incidence in African‑American, Northern European, and Caribbean populations.
• Age – Peak onset between 20–40 years, though children and older adults can be affected.
• Environmental exposure – Inhalation of organic dust, wood smoke, or certain metal particles has been linked to sarcoidosis clusters.
• Other autoimmune disorders – Co‑occurrence with rheumatoid arthritis, lupus, or inflammatory bowel disease may raise risk.

Diagnosis

Diagnosing ocular sarcoidosis involves a combination of clinical eye examination, systemic work‑up, and imaging. No single test is definitive; rather, the diagnosis rests on a pattern of findings that fit established criteria (e.g., International Workshop on Ocular Sarcoidosis, 2018).

Step‑by‑step evaluation

1. Comprehensive ophthalmic exam – Slit‑lamp biomicroscopy (anterior segment), funduscopy, and optical coherence tomography (OCT) to detect retinal or choroidal lesions.
2. Laboratory testing
   • Serum angiotensin‑converting enzyme (ACE) – Elevated in ~60 % of systemic sarcoidosis cases.
   • Serum lysozyme – May be raised.
   • Complete blood count, calcium, and liver function – To assess systemic involvement.
3. Imaging
   • Chest X‑ray or high‑resolution CT – Looks for hilar lymphadenopathy, a hallmark of sarcoidosis.
   • Fluorescein angiography (FA) – Highlights retinal vasculitis or leakage.
   • Indocyanine green angiography (ICGA) – Detects choroidal granulomas not visible on FA.
   • Ocular OCT‑angiography – Provides non‑invasive vascular mapping.
4. Biopsy (when needed) – Conjunctival, lacrimal gland, or skin biopsies that reveal non‑caseating granulomas can confirm the diagnosis when ocular findings are ambiguous.
5. Systemic evaluation – Pulmonology, rheumatology, or dermatology referrals to rule out other organ involvement.

In practice, a “clinical diagnosis” is often made when the eye shows characteristic signs (e.g., mutton‑fat keratic precipitates, vitritis, “candle‑wax” retinal lesions) together with systemic clues.

Treatment Options

Treatment aims to control inflammation, preserve vision, and address systemic disease. Therapy is individualized based on severity, location of inflammation (anterior, intermediate, posterior, or pan‑uveitis), and patient tolerance.

First‑line medications

• Topical corticosteroids (e.g., prednisolone acetate 1 %) – For mild anterior uveitis.
• Periocular (sub‑Tenon) steroid injections – Deliver high drug levels to posterior segment while limiting systemic exposure.
• Systemic corticosteroids (oral prednisone 0.5–1 mg/kg/day) – Mainstay for intermediate, posterior, or bilateral disease.

Steroid‑sparing agents (immunomodulatory therapy)

Long‑term steroid use carries risks (glaucoma, cataract, osteoporosis). Steroid‑sparing agents are introduced when:

• Inflammation recurs on tapering steroids, or
• High‑dose steroids are required for >3 months.

• Methotrexate – 7.5–25 mg weekly, often combined with folic acid.
• Mycophenolate mofetil – 1–2 g daily, useful for posterior uveitis.
• Azathioprine – 2–2.5 mg/kg/day.
• Biologic agents – Anti‑TNF‑α drugs (adalimumab, infliximab) have FDA approval for non‑infectious uveitis and show excellent response in refractory ocular sarcoidosis.<sup>Cleveland Clinic</sup>

Adjunctive therapies

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – Helpful for mild pain or arthritic sarcoid symptoms.
• Intra‑ocular pressure (IOP) control – Timolol, latanoprost, or selective laser trabeculoplasty if steroid‑induced glaucoma develops.
• Cataract surgery – Performed after inflammation is quiescent for ≥3 months.

Lifestyle & supportive measures

• Protect eyes from bright light (UV‑blocking sunglasses).
• Maintain adequate hydration and a balanced diet rich in omega‑3 fatty acids (anti‑inflammatory).
• Quit smoking – Smoking worsens granulomatous inflammation.
• Regular follow‑up with an ophthalmologist (every 4–6 weeks during active disease).

Living with Uveitis Granulomatosa (Sarcoidosis of the Eye)

Managing a chronic eye condition involves both medical and practical daily steps.

Practical tips

• Medication adherence – Use pill boxes or smartphone reminders; never stop steroids abruptly.
• Eye‑drop technique – Tilt head back, pull lower lid down, apply drop without touching the eye, close eyelid gently for 1 minute.
• Vision monitoring – Keep a log of any changes in clarity, floaters, or photophobia and report promptly.
• Protective eyewear – Sunglasses with 100 % UV protection reduce photophobia and help prevent secondary eye strain.
• Regular systemic check‑ups – Sarcoidosis can affect lungs, heart, skin, and nerves. Coordinated care reduces overall disease burden.
• Stress management – Chronic inflammation can be exacerbated by stress; consider mindfulness, yoga, or counseling.

Support resources

• Foundation for Sarcoidosis Research
• Uveitis Foundation
• Patient support groups (online forums, local meet‑ups)

Prevention

Because the exact trigger of sarcoidosis is unknown, primary prevention is limited. However, the following measures can lower the risk of ocular flares or reduce disease severity:

• Avoid smoking and occupational exposure to silica, beryllium, or metal dust.
• Control systemic sarcoidosis aggressively with appropriate medications.
• Promptly treat any respiratory infection—some studies suggest infections may precipitate granuloma formation.
• Schedule routine eye examinations (at least annually) for anyone diagnosed with systemic sarcoidosis, even if asymptomatic.

Complications

If inflammation is not controlled, several sight‑threatening complications can arise:

• Glaucoma – Steroid‑induced or inflammation‑related elevation of IOP.
• Cataract formation – Particularly posterior subcapsular cataracts from chronic steroid use.
• Macular edema – Fluid accumulation in the central retina, leading to central vision loss.
• Epiretinal membrane – Scar tissue on the retinal surface causing distortion.
• Choroidal neovascularization – Abnormal blood vessels that can bleed and scar.
• Permanent vision loss – From retinal damage or optic nerve involvement.

When to Seek Emergency Care

---

© 2026 HealthGuide™ – All information is for educational purposes only and does not replace professional medical advice. Consult an eye‑care specialist or your primary physician for personalized evaluation.

```